IL91275A - תכשיר חומצות שומניות המורכב בעיקרו מחומצה )z-lla(-5, 8, 11, 41, 71, איקוזאפנטאאנואית וחומצה )z-lla(-4,7,01, 31, 61, 91- דוקוזאהקסא - Google Patents

תכשיר חומצות שומניות המורכב בעיקרו מחומצה )z-lla(-5, 8, 11, 41, 71, איקוזאפנטאאנואית וחומצה )z-lla(-4,7,01, 31, 61, 91- דוקוזאהקסא

Info

Publication number
IL91275A
IL91275A IL9127589A IL9127589A IL91275A IL 91275 A IL91275 A IL 91275A IL 9127589 A IL9127589 A IL 9127589A IL 9127589 A IL9127589 A IL 9127589A IL 91275 A IL91275 A IL 91275A
Authority
IL
Israel
Prior art keywords
weight
acid
fatty acids
epa
dha
Prior art date
Application number
IL9127589A
Other languages
English (en)
Other versions
IL91275A0 (en
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10641979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL91275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of IL91275A0 publication Critical patent/IL91275A0/xx
Publication of IL91275A publication Critical patent/IL91275A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL9127589A 1988-08-11 1989-08-10 תכשיר חומצות שומניות המורכב בעיקרו מחומצה )z-lla(-5, 8, 11, 41, 71, איקוזאפנטאאנואית וחומצה )z-lla(-4,7,01, 31, 61, 91- דוקוזאהקסא IL91275A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888819110A GB8819110D0 (en) 1988-08-11 1988-08-11 Antihypertensive drug & method for production

Publications (2)

Publication Number Publication Date
IL91275A0 IL91275A0 (en) 1990-03-19
IL91275A true IL91275A (he) 1996-01-19

Family

ID=10641979

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9127589A IL91275A (he) 1988-08-11 1989-08-10 תכשיר חומצות שומניות המורכב בעיקרו מחומצה )z-lla(-5, 8, 11, 41, 71, איקוזאפנטאאנואית וחומצה )z-lla(-4,7,01, 31, 61, 91- דוקוזאהקסא

Country Status (24)

Country Link
US (3) US5502077A (he)
JP (1) JP2810916B2 (he)
KR (1) KR0126286B1 (he)
AT (1) AT398779B (he)
AU (1) AU616784B2 (he)
BE (1) BE1002547A5 (he)
CA (1) CA1337548C (he)
CH (1) CH680789A5 (he)
DE (1) DE3926658C2 (he)
DK (1) DK173371B1 (he)
ES (1) ES2018384A6 (he)
FI (1) FI893805A (he)
FR (1) FR2635263A1 (he)
GB (2) GB8819110D0 (he)
GR (1) GR1000567B (he)
HK (1) HK84196A (he)
IE (1) IE64524B1 (he)
IL (1) IL91275A (he)
IT (1) IT1235879B (he)
LU (1) LU87570A1 (he)
NL (1) NL193459C (he)
NZ (1) NZ230022A (he)
SE (1) SE504742C2 (he)
ZA (1) ZA895512B (he)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
DK198991D0 (da) * 1991-12-10 1991-12-10 Simanol A S Fiskeprodukt
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
DK0697034T3 (da) * 1993-04-29 1997-07-14 Norsk Hydro As Fremgangsmåder til kromatografisk fraktionering af fedtsyrer og deres derivater
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
WO1995009622A1 (en) * 1993-10-06 1995-04-13 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
GB9404483D0 (en) * 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6020020A (en) * 1995-11-24 2000-02-01 Loders-Croklaan B.V. Composition based on fish oil
US5866150A (en) * 1996-03-20 1999-02-02 Aquaculture Technology Incorporated Antibacterially active extracts from the marine algae chaetoceros and methods of use
EP1004303B1 (en) 1997-06-16 2004-10-13 Nippon Suisan Kaisha, Ltd. Composition having capability of removing risk factor during exercise
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US6992057B2 (en) * 2000-02-22 2006-01-31 The Procter & Gamble Company Fatty acids, soaps, surfactant systems, and consumer products based thereon
WO1999020722A2 (en) * 1997-10-23 1999-04-29 The Procter & Gamble Company Fatty acids, soaps, surfactant systems, and consumer products based thereon
NO309795B1 (no) * 1998-07-01 2001-04-02 Norsk Hydro As FremgangsmOte for O stabilisere oljer samt anvendelse derav, fremgangsmOte for O stabilisere pigmenter, og fremgangsmOte for fremstilling av for
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6998501B1 (en) 1999-08-30 2006-02-14 Ocean Nutrition Canada Limited Nutritional supplement for lowering serum triglyceride and cholesterol levels
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
US6395778B1 (en) 2000-01-11 2002-05-28 Omegatech, Inc. Process for making an enriched mixture of polyunsaturated fatty acid esters
US20020016314A1 (en) * 2000-01-31 2002-02-07 Schersl Endre Markovits Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
EP1157692B1 (en) * 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
NZ518504A (en) * 2002-04-22 2005-05-27 Ind Res Ltd Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
DE60328785D1 (de) * 2002-06-17 2009-09-24 Medestea Res & Production S P Langkettige ungesättigte sauerstoffhaltige verbindungen und deren verwendung im therapeutischen, kosmetischen und diätetischen bereich
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (en) * 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
US7279018B2 (en) 2002-09-06 2007-10-09 Fortum Oyj Fuel composition for a diesel engine
US7041840B2 (en) * 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
DE10261061A1 (de) * 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
US20040235948A1 (en) * 2003-03-05 2004-11-25 Solvay Pharmaceuticals Gmbh Treatment of diabetic patients with omega-3-fatty acids
DE10317109A1 (de) * 2003-04-14 2004-11-11 Cognis Deutschland Gmbh & Co. Kg Zubereitungen zur oralen Aufnahme
US7759507B2 (en) * 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1656935A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for the treatment of pruritus
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
CN103058867B (zh) * 2005-05-04 2015-03-25 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
WO2006123550A1 (ja) * 2005-05-16 2006-11-23 Nippon Suisan Kaisha, Ltd. 炎症性疾患予防又は治療剤
US20060292217A1 (en) * 2005-06-03 2006-12-28 Schmidt Robbin D Nutritional supplement and soft gelatin capsule delivery system
CA2616806A1 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
DE102005040463A1 (de) 2005-08-26 2007-03-01 Cognis Ip Management Gmbh Verwendung von Gemischen aus Polyphenolen und physiologisch aktiven ungesättigten Fettstoffen
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
DE102005054577A1 (de) 2005-11-16 2007-05-24 Cognis Ip Management Gmbh Verwendung von Estern ungesättigter, physiologisch aktiver Fettsäuren als Nährmedien für Zellkulturen
EP1957039A2 (en) * 2005-12-09 2008-08-20 Drugtech Corporation Intravenous essential fatty acid emulsion
NZ569068A (en) * 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
WO2007081773A2 (en) * 2006-01-05 2007-07-19 Reliant Pharmaceuticals, Inc Treatment of fatty liver
EP1991196B1 (en) 2006-03-03 2016-10-12 Fmc Corporation Method and apparatus for the preparation of capsules.
JP5628480B2 (ja) 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー 医薬成分を含有するコーティングカプセル
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007142118A1 (ja) * 2006-05-31 2007-12-13 Mochida Pharmaceutical Co., Ltd. 多重リスク患者の心血管イベント発症予防用組成物
WO2008011178A2 (en) * 2006-07-21 2008-01-24 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
WO2008088415A1 (en) * 2006-10-18 2008-07-24 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for reduction of lp-pla2 levels
MX2009004336A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar).
BRPI0717972A2 (pt) * 2006-11-01 2013-11-12 Pronova Biopharma Norge As Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
RU2009120568A (ru) 2006-11-01 2010-12-10 Пронова Биофарма Норге Ас (No) Композиция
JP5552314B2 (ja) * 2006-11-01 2014-07-16 プロノヴァ バイオファーマ ノルゲ アーエス 新規脂質化合物
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
KR20090077081A (ko) * 2006-11-03 2009-07-14 프로노바 바이오파마 노르지 에이에스 지방산 알코올
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1967197A1 (en) * 2007-03-09 2008-09-10 Cognis IP Management GmbH Use of preparations, purifications and extracts of aloe
WO2009052182A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
WO2009006317A1 (en) * 2007-06-29 2009-01-08 Martek Biosciences Corporation Production and purification of esters of polyunsaturated fatty acids
AU2008272135B2 (en) * 2007-06-29 2013-10-31 Takeda Pharmaceutical Company Limited Seamless capsule
WO2009009040A2 (en) * 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2224911A4 (en) * 2007-11-30 2013-05-08 Jbs United Inc METHOD AND COMPOSITION FOR TREATING LUNG HAEMORRHAGIA
US8575409B2 (en) 2007-12-20 2013-11-05 Syntroleum Corporation Method for the removal of phosphorus
BRPI0822019A2 (pt) 2008-01-10 2015-07-21 Takeda Pharmaceutical Cápsula sem costura
US20090182049A1 (en) * 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
EP2291499B1 (en) 2008-05-15 2020-02-12 Basf As Krill oil process
US20090300971A1 (en) 2008-06-04 2009-12-10 Ramin Abhari Biorenewable naphtha
US8581013B2 (en) 2008-06-04 2013-11-12 Syntroleum Corporation Biorenewable naphtha composition and methods of making same
DK2323647T3 (en) 2008-08-07 2014-12-08 Prodotti Antibiotici Spa LONG-TERM TREATMENT OF symptomatic heart failure
EP3578177A1 (en) * 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
WO2010040012A1 (en) * 2008-10-01 2010-04-08 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
US8231804B2 (en) 2008-12-10 2012-07-31 Syntroleum Corporation Even carbon number paraffin composition and method of manufacturing same
US8563792B2 (en) * 2008-12-16 2013-10-22 Cetane Energy, Llc Systems and methods of generating renewable diesel
CA2750153C (en) 2009-01-05 2016-11-08 Calanus As Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease
DK3037089T3 (da) 2009-02-10 2020-01-20 Amarin Pharmaceuticals Ie Ltd Eicosapentaensyreethylester til behandling af hypertriglyceridæmi
KR101841756B1 (ko) * 2009-03-09 2018-03-23 프로노바 바이오파마 너지 에이에스 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
PT2429317T (pt) 2009-04-17 2016-07-22 Natac Pharma S L Composições ricas em ácidos gordos ómega-3 com um teor baixo de ácido fitânico
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
KR101357438B1 (ko) 2009-04-29 2014-02-06 아마린 코포레이션 피엘씨 Ｅｐａ 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
NZ597193A (en) 2009-06-15 2014-01-31 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9101942B2 (en) 2009-06-16 2015-08-11 Aurora Algae, Inc. Clarification of suspensions
US20110033595A1 (en) * 2009-08-10 2011-02-10 Rudolf Krumbholz Fatty acid fractionation process, fatty acid products and use thereof
US20110033531A1 (en) * 2009-08-10 2011-02-10 Dracopharma, Inc. Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
BR112012005452B1 (pt) * 2009-09-10 2021-05-11 DuPont Nutrition USA, Inc. cápsula de alginato sem costura, e, método para fabricar uma cápsula de alginato sem costura
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US20110082205A1 (en) * 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
KR101904388B1 (ko) * 2009-10-23 2018-10-05 프로노바 바이오파마 너지 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
AU2013204090B2 (en) * 2009-12-30 2015-01-29 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
KR101761959B1 (ko) * 2009-12-30 2017-07-26 바스프 파마 (칼라니쉬) 리미티드 다중 불포화 지방산을 정제하기 위한 시뮬레이션된 이동상 크로마토그래피 분리 방법
US20110178105A1 (en) * 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
AU2011222544A1 (en) * 2010-03-04 2012-09-27 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8394900B2 (en) 2010-03-18 2013-03-12 Syntroleum Corporation Profitable method for carbon capture and storage
WO2011143587A1 (en) 2010-05-13 2011-11-17 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
EP2593141B1 (en) * 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20140004186A1 (en) * 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
WO2012032417A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CL2010001587A1 (es) * 2010-12-27 2013-01-11 Golden Omega S A Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013068846A1 (en) 2011-11-09 2013-05-16 Pronova Biopharma Norge As Membrane-based processes for reducing at least one impurity and making a concentrate comprising at least one natural component from a marine fatty acid oil mixture, and compositions resulting thereof
KR101466617B1 (ko) 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
PT2800563T (pt) 2012-01-06 2018-11-07 Chrysalis Pharma Ag Composições enriquecidas com dpa de ácidos gordos omega-3 polinsaturados sob a forma de ácido livre
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
AU2013201793B2 (en) * 2012-01-06 2015-03-19 Chrysalis Pharma Ag DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2819675A4 (en) * 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
RU2633862C2 (ru) 2012-03-30 2017-10-18 Санчилио Энд Компани, Инк. Композиции сложных эфиров омега-3 жирных кислот
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
HUE036187T2 (hu) 2012-04-30 2018-06-28 Tillotts Pharma Ag Késleltetett leadású gyógyszerkészítmény
TW201347754A (zh) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc 史他汀及ω－３脂肪酸之組合物
US9540306B2 (en) * 2012-05-14 2017-01-10 Nippon Suisan Kaisha, Ltd. Highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester with reduced environmental pollutants, and method for producing same
CA2916208A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
SG10201913646PA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014060847A1 (en) 2012-09-24 2014-04-24 Aker Biopharma As Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
EP2897595B1 (en) 2012-09-24 2020-06-03 Aker Biomarine Antarctic As Omega -3 compositions
WO2014063190A1 (en) * 2012-10-23 2014-05-01 Deakin University Method for reducing triglycerides
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
EP3888646A1 (en) * 2012-12-06 2021-10-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014134053A1 (en) * 2013-02-26 2014-09-04 Jiva Pharma, Inc. Ascorbate esters of omega-3 fatty acids
US9328303B2 (en) 2013-03-13 2016-05-03 Reg Synthetic Fuels, Llc Reducing pressure drop buildup in bio-oil hydroprocessing reactors
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US20140274922A1 (en) 2013-03-15 2014-09-18 Aurora Algae, Inc. Algal omega 7 compositions
US9266973B2 (en) 2013-03-15 2016-02-23 Aurora Algae, Inc. Systems and methods for utilizing and recovering chitosan to process biological material
US8969259B2 (en) 2013-04-05 2015-03-03 Reg Synthetic Fuels, Llc Bio-based synthetic fluids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2923063C (en) 2013-10-29 2021-09-07 Tillotts Pharma Ag A delayed release drug formulation
MX2016004487A (es) 2013-10-30 2016-11-10 Banner Life Sciences Llc Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
CA2929954A1 (en) * 2013-11-08 2015-05-14 Omega Protein Corporation Purification of dpa enriched oil
EP2883860B1 (fr) 2013-12-11 2016-08-24 Novasep Process Procédé chromatographique de production d'acides gras polyinsaturés
WO2015104464A1 (fr) 2014-01-07 2015-07-16 Novasep Process Procédé de purification d'acides aminés aromatiques
CA2950344C (en) 2014-06-06 2023-09-19 Marine Ingredients, Llc Omega-3 compositions, dosage forms, and methods of use
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US9895333B2 (en) * 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
TWI532482B (zh) * 2014-09-01 2016-05-11 國立中山大學 阿魏酸用以製備提升血紅蛋白釋放氧氣至人體內各器官及周邊組織能力之藥物的用途
JP6816012B2 (ja) * 2015-03-26 2021-01-20 ティベリオ ブリュジーズ 多価不飽和脂肪酸の精製方法
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3219209A1 (de) 2016-03-19 2017-09-20 DMK Deutsches Milchkontor GmbH Lagerstabile milchzubereitung enthaltend ascorbinsäure
CA3029262A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
IT201700054543A1 (it) 2017-05-19 2018-11-19 Gleaner Srls Preparato come fonte di Omega-3
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190385718A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158541A (en) * 1959-12-18 1964-11-24 Escambia Chem Corp Product for reduction of blood cholesterol concentration
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
AU527784B2 (en) * 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
GB1604554A (en) * 1978-05-26 1981-12-09 Dyerberg J Pharmaceutical and food formulations
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
JPS59172416A (ja) * 1983-03-18 1984-09-29 Terumo Corp 脂肪輸液
GB2140806B (en) * 1983-05-28 1987-10-28 Sekimoto Hiroshi Stabilisation of unsaturated fatty acids, fish oils or fish
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS60133094A (ja) * 1983-12-21 1985-07-16 日清製油株式会社 高純度エイコサペンタエン酸の製造法
EP0175468A3 (en) * 1984-08-10 1987-07-22 Sentrachem Limited Eicosanoids for use in cancer therapy
US4675132A (en) * 1985-03-28 1987-06-23 The United States Of America As Represented By The Secretary Of Commerce Polyunsaturated fatty acids from fish oils
GB8524276D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
NO157302C (no) * 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
JPS6388159A (ja) * 1986-09-30 1988-04-19 Nippon Oil & Fats Co Ltd ドコサヘキサエン酸エステルの製造法
GB2197199B (en) * 1986-11-13 1991-04-03 Efamed Medicament for treatment of pregnancy-induced hypertension.
DE3643848A1 (de) * 1986-12-22 1988-09-01 Natec Inst Naturwiss Verfahren zur herstellung hochraffinierter essbarer glyceridoele mit einem anteil an ungesaettigten fettsaeuren im triglyceridverband und ihre verwendung
GB8705459D0 (en) * 1987-03-09 1987-04-15 Efamol Ltd Treatment of peptic ulcers
HU202088B (en) * 1987-03-18 1991-02-28 Caola Kozmetikai Method for producing dietetic preparation
HU203660B (en) * 1987-04-23 1991-09-30 Biogal Gyogyszergyar Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses

Also Published As

Publication number Publication date
US5698594A (en) 1997-12-16
ATA191889A (de) 1994-06-15
NZ230022A (en) 1990-10-26
AU3896789A (en) 1990-02-15
GB8917711D0 (en) 1989-09-20
GB8819110D0 (en) 1988-09-14
KR900002771A (ko) 1990-03-23
FI893805A0 (fi) 1989-08-11
DE3926658A1 (de) 1990-02-15
FI893805A (fi) 1990-02-12
LU87570A1 (fr) 1990-01-08
US5502077A (en) 1996-03-26
HK84196A (en) 1996-05-24
US5656667A (en) 1997-08-12
IE892317L (en) 1990-02-11
ZA895512B (en) 1990-07-25
KR0126286B1 (ko) 1997-12-26
IE64524B1 (en) 1995-08-09
GR1000567B (el) 1992-08-26
NL8902020A (nl) 1990-03-01
DK392089D0 (da) 1989-08-10
SE8902701D0 (sv) 1989-08-09
NL193459C (nl) 1999-11-02
DK392089A (da) 1990-02-12
ES2018384A6 (es) 1991-04-01
DE3926658C2 (de) 1998-10-15
NL193459B (nl) 1999-07-01
GB2221843A (en) 1990-02-21
IL91275A0 (en) 1990-03-19
CA1337548C (en) 1995-11-14
GB2221843B (en) 1992-12-02
SE504742C2 (sv) 1997-04-14
JP2810916B2 (ja) 1998-10-15
FR2635263B1 (he) 1992-02-14
AU616784B2 (en) 1991-11-07
BE1002547A5 (fr) 1991-03-19
JPH02104522A (ja) 1990-04-17
FR2635263A1 (en) 1990-02-16
IT1235879B (it) 1992-11-23
CH680789A5 (he) 1992-11-13
AT398779B (de) 1995-01-25
DK173371B1 (da) 2000-09-04
IT8921521A0 (it) 1989-08-11
SE8902701L (sv) 1990-02-12
GR890100507A (en) 1990-08-22

Similar Documents

Publication Publication Date Title
US5656667A (en) Fatty acid composition
US4407821A (en) Lipidic compositions for use in dietetics, reanimation and therapeutics
US4970076A (en) Fatty acid composition
JP2796838B2 (ja) 精神分裂症および／または関連した晩発性運動障害の治療のための薬剤を製造する方法
EP0115419B1 (en) The use of linoleic and alpha-linolenic acid metabolites for the preparation of pharmaceutical or dietary compositions for treatment of atopic disorders
EP0782827B1 (en) Use of a balancing agent for omega-6 and omega-3 unsaturated fatty acids
GB2148713A (en) Pharmaceutical composition and food product comprising higher fatty acids
JPH0733655A (ja) 医薬組成物
JPH0779661B2 (ja) 食品組成物
US4898885A (en) Pharmaceutica and dietary compositions
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed